Axillary nodal metastasis in ovarian cancer: a report of three cases and review of literature

Mohammad Zuhdy1*, Reham Alghandour2, Gena Abdelazeem3, Gehad A. Saleh4, Mahmoud M. Saleh1, Mohamed Hamdy1 and Omar Hamdy1

Abstract

Background: Ovarian cancer represents a major global health burden that is rarely associated with distant metastasis. Axillary lymph node metastasis from ovarian cancer is rare and is reported only in few case reports in literature.

Case presentation: We report three cases of ovarian carcinoma associated with axillary lymph node metastasis as well as a brief literature review. The pathologic subtype in one case was malignant mixed Mullerian tumor, while the other two cases were high-grade serous ovarian carcinoma. Axillary nodal metastasis was reported as a synchronous event in one case, while it was reported as recurrence events in the other two cases.

Conclusion: Physicians should be aware of this uncommon mode of metastasis in ovarian cancer cases. Multi-disciplinary discussion is crucial in the management of these cases to offer them the best suitable treatment.

Keywords: Ovarian cancer, Axillary metastasis, Case report, Neoplasm, Metastasis

Background

Ovarian cancer represents a major global health burden accounting for 3.4% of newly diagnosed cancer cases and 4.4% of cancer mortality among females, where most patients die within 5 years of initial diagnosis [1, 2]. This could be attributed to the advanced disease stage at which most patients are presented that makes treatment strategies less efficient [3]. Ovarian cancer mainly metastasizes through intraperitoneal route either to Douglas pouch, paracolic gutters, liver and splenic capsules, omentum, or small intestinal mesentery where it remains confined throughout the disease course [4]. Distant metastasis from ovarian cancer is a rare event where the liver, lung, or pleura are most commonly involved [5]. Axillary lymph node metastasis from ovarian cancer is rare [6] and is reported only in few case reports in literature. Hereby, we present three cases of ovarian serous carcinoma associated with axillary lymph node metastasis as well as a brief literature review.

Case presentation

Case no. 1

A 69-year-old lady without a relevant medical history complaining of vague abdominal symptoms. Abdominal ultrasound and computerized tomography (CT) scan revealed bilateral adnexal masses, omental, peritoneal deposits, and two hypodense hepatic focal lesions, serum cancer antigen 125 (CA 125) was markedly elevated 990 u/ml (normal limit up to 35 u/ml). Core needle biopsy from the omental lesion revealed metastasis from ovarian carcinoma confirmed by positive immune histochemical (IHC) staining for cytokertatin 7 (CK7), Wilms' Tumor 1 (WT-1), and negative CK20. Our tumor board recommended neoadjuvant chemotherapy, so the patient received 3 cycles of neoadjuvant (Taxol/carboplatin) regimen. Re-evaluation CT revealed the disappearance of the hepatic and peritoneal lesions, so interval suboptimal debulking was performed in January 2014 in the form of total abdominal hysterectomy, bilateral salping-
A 39-year-old lady with a history of previous right oophorectomy due to ruptured ectopic pregnancy. She was referred to our center in December 2016 after performing left ovarian cystectomy with a postoperative pathology report that revealed papillary serous cystadenocarcinoma. Preoperative MRI revealed multilocular ovarian cystic lesion about 6.5 × 7 × 8 cm with mural nodules, septae, and central solid component. It was associated with minimal free fluid in Douglas pouch as well as hemorrhagic peritoneal nodules. Serum CA 125 was mildly elevated (CA 125 = 87). General examination revealed enlarged right-sided axial lymph node, so a bilateral breast and axilla sonomammography was requested but it revealed no breast lesions except for the enlarged lymph node from which a fine needle aspiration cytology revealed metastatic papillary adenocarcinoma of ovarian origin confirmed by the positivity of CK7 and WT-1 and negativity of CK20 and mammoglobin. The tumor board recommended proceeding to cytoreductive surgery where total abdominal hysterectomy, left salping-oophrectomy, infracolic omentectomy, excision of peritoneal nodules over the diaphragm and in the pelvis, and right-sided axillary clearance were done. The rationale for performing axillary clearance rather than axillary lymph node excision was to accomplish complete cytoreduction through minimizing the incidence of leaving micrometastasis in any unexcised axillary nodes. Histopathological examination of the specimen revealed high-grade papillary serous cystadenocarcinoma with deposits in the omentum, the peritoneum, and one out of 17 dissected axillary lymph nodes. The patient had a smooth postoperative course then she was referred to a medical oncologist to receive her adjuvant therapy, after which she lost follow-up with our department.

Case no. III

A 58-year-old postmenopausal lady with a medical history of hypertension and heart failure was presented in April 2016 with a complaint of abdominal enlargement and vague abdominal pain. CT scan revealed large right side malignant adnexal mass 14 × 12 × 10 cm with moderate ascites, enlarged iliac and paraortic lymph nodes, and large peritoneal nodules. This scan also revealed multiple enlarged axillary lymph nodes. Serum CA-125 was markedly elevated 720 u/ml (normal range = up to 35 u/ml), while bilateral sonomammography did not reveal any suspicious lesions. A fine needle aspiration cytology (FNAC) from right-sided enlarged axillary lymph nodes revealed metastatic carcinoma of ovarian origin confirmed by positive WT-1 and negative CK7, CK20, inhibin, and leukocyte common antigen (LCA). Multi-disciplinary board meeting recommended starting neoadjuvant chemotherapy where the patient received 6 cycles of Taxol/carboplatin regimen, after which follow-up CT showed modest response with decreased size of the axillary, iliac, and paraortic lymph nodes and peritoneal masses. Bilateral sonomammography revealed a complete disappearance of the axillary nodal disease. Considering the poor performance status of the patient and the radiological response in the axillary nodes, a cytoreductive surgery was planned where total abdominal hysterectomy, bilateral salping-oophrectomy, infracolic omentectomy, and sampling of enlarged iliac lymph nodes were done. The postoperative pathological assessment revealed infiltration of both ovaries by papillary serous carcinoma confirmed by being positive for IHC WT-1, CK7, and P53 and negative for CK20 with free omentum but infiltrated iliac lymph nodes and excised peritoneal nodules. The patient had a smooth postoperative course after which she was referred back to the clinical oncologist to continue her adjuvant therapy where she received three cycles of Taxol/carboplatin regimen. She was then maintained on follow-up till she was lost to follow-up after her last visit on 11 October 2017.
Discussion

Nearly 75% of ovarian cancer cases are diagnosed at an advanced stage (FIGO III–IV) [7]. Lymph node metastasis is considered an unusual presentation of carcinoma of the ovary as it commonly spreads by intraperitoneal route, local infiltration, or both of them leading to intra-abdominal disease with ascites and/or pleural effusion [8]. Distant metastasis is reported in stage IV disease either through lymphatic route or through hematogenous dissemination to the lungs, liver, pleura, brain, and distant lymph nodes, which is considered rare in the primary presentation of ovarian carcinoma [9].

The most commonly reported sites of lymph node metastasis from ovarian cancer are para-aortic (38%), mediastinal (29%), and pelvic (19%) while less commonly involved lymph node groups are supra-clavicular (4%) and inguinal (3%) [10, 11].

Ovarian cancer metastasis to the breast is rare representing 0.03–0.6% of all breast malignancies [12]. However, isolated axillary nodal metastasis from ovarian cancer is very rare and had been reported in just a few case reports [13].

The most common causes of malignant axillary lymphadenopathy with negative mammography include lymphoma, melanoma, and lung, stomach, or ovarian carcinoma [14].

To the best of our knowledge, 27 cases of axillary lymph node metastasis from ovarian cancer have been reported in English-based literature. A summary of their characteristics is available in Table 1.

The most commonly reported ovarian cancer subtype that metastasizes to axillary lymph nodes is the serous subtype [12] which is the subtype reported in two of our three cases.

Whenever tumors in axillary lymph nodes are found simultaneously with ovarian cancer, a diagnostic dilemma is considered. The use of immune histochemical markers may aid in diagnosis as WT-1, CK 7, and CK 20. Cytokeratin 7 and 20 are low molecular weight cytokeratins that confirm the epithelial origin of the metastasis either from the breast or from the ovary [26]. Al-Hussaini et al. reported 94.7% of ovarian serous carcinoma to be positive for WT-1 [27].

Axillary nodal metastasis from ovarian cancer can be explained by the fact that ovarian cancer commonly presents by ascites and peritoneal carcinomatosis; hence, transdiaphragmatic invasion is possible to the superior diaphragmatic lymph nodes. From these nodes, further metastasis could follow one of two pathways. The first one is the anterior to the prepericardial lymph nodes then either to the internal jugular and subclavian veins or to the subclavian lymph trunk ending eventually into axillary lymph nodes. The second is the posterior one to deep lymphatic vessels inferior to the diaphragm and superficial lymphatic vessels inferior to the umbilicus which unites forming cisterna chyli and thoracic duct ending eventually in the junction between the left subclavian and internal jugular vein [28].

Table 1 Literature review of previously reported cases of metastatic ovarian carcinoma to axillary lymph nodes

| Author/year | No. of cases | Age | Presentation | Pathological type | Treatment |
|-------------|--------------|-----|--------------|------------------|-----------|
| Hockstein 1997 [15] | 1 | 78 | Synchronous | Poorly differentiated adenocarcinoma | Platinum-based chemotherapy |
| Orris 1999 [16] | 1 | 63 | Recurrence | Not available | Axillary dissection |
| Recine 2004 [12] | 6 | 21-67 | 2 synchronous/4 recurrence | Serous | Chemotherapy |
| Ozmen 2007 [17] | 2 | 74/38 | Recurrence | Papillary serous | Surgery |
| Legge 2008 [18] | 1 | Not available | Recurrence | Not available | Not available |
| Skagias 2008 [10] | 1 | 63 | Recurrence | Poorly differentiated adenocarcinoma | Not available |
| Aydin 2008 [4] | 1 | 47 | Recurrence | Serous | Excision + chemotherapy |
| Sughayer 2009 [19] | 1 | 63 | Synchronous + collision mets from breast cancer | Serous | Surgery |
| Harrison 2010 [20] | 1 | 47 | Synchronous | Not available | Chemotherapy |
| Demir 2012 [21] | 1 | 52 | Recurrence | Serous | Chemotherapy |
| Goyal 2012 [3] | 1 | 68 | Recurrence | Serous | Excision |
| Choi 2014 [22] | 1 | 68 | Synchronous | Serous | Interval debulking surgery |
| Patel 2014 [23] | 1 | 50 | Recurrence | Serous | Not available |
| Sibio 2014 [24] | 1 | 49 | Synchronous | Not available | Cytoreductive surgery |
| Mason 2015 [6] | 1 | 58 | Synchronous | Serous | Chemotherapy |
| Ilhan 2016 [13] | 6 | 50-80 | Synchronous | Serous | Interval debulking in 5 patients, chemotherapy only in one patient |
| Eitan 2017 [25] | 2 | 51/70 | Synchronous | Serous | Interval debulking |
Conclusions
To conclude, physicians should be aware of this uncommon mode of metastasis in ovarian cancer cases. This could not be encountered unless there are thorough physical examination and surveillance strategies of advanced ovarian cancer patients. Multi-disciplinary discussion is crucial in the management of these cases to offer them the best suitable treatment.

Abbreviations
CA 125: Cancer antigen 125; CK7, CK20: Cytokeratin 7,20; CT: Computed tomography; ER: Estrogen receptor; FIGO: Fédération Internationale de Gynécologie et d’Obstétrique; FNAC: Fine needle aspiration cytology; IHC: Immuno-histochemical stains; LCA: Leukocyte common antigen; MRI: Magnetic resonance imaging; PR: Progesterone receptor; WT-1: Wilms’ Tumor-1

Acknowledgements
Not applicable.

Authors’ contributions
MZ wrote the manuscript. RA wrote the case presentations and oncological follow-up of the cases. GAA contributed to the pathological interpretation. GAS contributed to the radiological interpretation. MMS wrote the case presentations and reformatted the manuscript. MH contributed to the literature review writing. OH revised the manuscript. All authors have read and approved the manuscript.

Funding
Not applicable.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
Ethics approval is not required due to the nature of reporting the study rather than conducting a planned case study on participants.

Consent for publication
A written informed consent was taken from each patient included in this report.

Competing interests
The authors declare that they do not have competing interests.

Author details
1Surgical Oncology Unit, Oncology Center, Mansoura University, Mansoura 35516, Egypt. 2Medical Oncology Unit, Oncology Center, Mansoura University, Mansoura, Egypt. 3Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 4Radiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Received: 2 September 2019 Revised: 6 November 2019 Accepted: 12 November 2019

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAn estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.
3. Goyal H, Matteo VK, Singla U. Isolated axillary lymph node metastasis from serous ovarian cancer. Case Rep Oncol Med. 2012;2012:307567.
4. Aydın C, Ünalp HR, Baloğlu A, Inci AG, Yüksel S, Yavuzcan A. Axillary lymph node metastasis from serous ovarian cancer: a case report and review of the literature. Arch Gynecol Obstet. 2009;279(2):203–7.
5. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003;13(2):125–9.
6. Mason C, Yoku fabricated K, Hamilton R, Oza U, Shah Z, Spigel J, et al. Unusual presentation of metastatic ovarian carcinoma as an enlarged intramammary lymph node. Proc (Bayl Univ Med Cent). 2015;28(3):386–8.
7. Prat J. Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.
8. Euscher ED, Silva EG, Deavers MT, Elisheva E, Gerdesen OM, Malpica A. Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol. 2004;28(9):1217–23.
9. Kamura T, Leon JD. Lymph node metastasis in a gynecologic malignancy. Oncol Med J. 2002;43(6):783–91.
10. Sugas T, Nitis A, Yasuo O, Kondi-Paffit A, Politi E. Ovarian carcinoma presenting with axillary lymph node metastasis: a case diagnosed by fine-needle aspiration and brief review of the literature. Diagn Cytopathol. 2008;36(12):891–3.
11. Dvoretzky PM, Richards KA, Angel C, Rabinowitz L, Beecham JB, Bonfiglio TA. Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum Pathol. 1988;19(11):1273–9.
12. Recine MA, Deavers MT, Middleton LP, Silva EG, Malpica A. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am J Surg Pathol. 2004;28(12):1646–51.
13. Ilhan B, Kılıc B, Karanlik H. Ovarian carcinoma presenting as an axillary mass: case series and literature review. Curr Res Transl Med. 2016;4(6):161–3.
14. Görmeli SB, O’Connell AM. Abnormal axillary lymph nodes on negative mammograms: causes other than breast cancer. Diagn Interv Radiol. 2012;18(3):473–9.
15. Hockstein S, Keh P, Lurain JR, Fishman DA. Ovarian carcinoma initially presenting as metastatic axillary lymphadenopathy. Gynecol Oncol. 1997;65(3):543–7.
16. Orris B, Geisler J, Geisler H. Ovarian carcinoma metastatic to bilateral axillary lymph nodes. A case report. Eur J Gynaecol Oncol. 1999;20(3):189–90.
17. Ozmen V, Asoglu O, Karanlik H, Cavcoglu N, Kecen M, Bakkaloglu B. Primary ovarian cancer presenting with axillary lymph node metastases: a report of two cases. Acta Chir Belg. 2007;107(1):175–7.
18. Legge F, Petillo M, Adorno V, Picconi S, Scambia G, Ferrandina G. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer. 2008;8(1):367.
19. Sughray MA, Zakerneh L, Abu-Shakra R. Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature. Pathol Oncol Res. 2009;15(3):423–7.
20. Harrison B, Lerner DJ, Tenofsky PL, Reddy PS. Ovarian adenocarcinoma presenting as axillary lymphadenopathy. Kans J Med. 2010(32):35–7.
21. Demir L, Erten C, Yigit SC, Can A, Dircan A, Bayoglu V, et al. Intramammary lymph node metastasis in a patient with ovarian carcinoma and a brief review of the literature. Contemp Oncol. 2012;16(2):108.
22. Choi Ji, Kim SJ, Park SH, Kim HG. Solitary axillary lymph node metastasis without breast involvement from ovarian cancer: case report and brief literature review. J Korean Soc Radiol. 2014;7(1):249–53.
23. Patel TS, Shah C, Shah MC, Shah MJ. Axillary node metastasis from primary ovarian carcinoma. J Cytol. 2014;31(4):202–4.
24. Sibio S, Sammartino P, Accarpo F, dei Malatesta Framarino M, Biacchi D, Solazzo B, et al. Axillary lymph node metastasis as first presentation of peritoneal carcinomatosis from serous papillary ovarian cancer: case report and review of the literature. Eur J Gynaecol Oncol. 2014;35(2):170–3.
25. Eitam R, Tsoref D, Sabah G, Saliman L. Axillary lymph node metastasis in ovarian carcinoma: two case reports and review of literature. Gynecol Oncol Rep. 2017;22:94–6.
26. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13(9):962.
27. Al-Hussaini M, Stockman A, Foster H, McCluggage W. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44(2):109–15.
28. Hynninen J, Auranen A, Carpen O, Dean K, Seppänen M, Kemppainen J, et al. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol. 2012;126(1):66–4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.